医学
内科学
转移性乳腺癌
曲妥珠单抗
Destiny(ISS模块)
肿瘤科
乳腺癌
癌症
天文
物理
作者
Cristina Saura,Shanu Modi,Ian E. Krop,Y.H. Park,S.-B. Kim,Kenji Tamura,Hitoshi Iwata,Junji Tsurutani,Joohyuk Sohn,E. Mathias,Y. Liu,Jillian Cathcart,Jasmeet Singh,Toshinari Yamashita
标识
DOI:10.1016/j.annonc.2023.12.001
摘要
Primary analysis of the multicenter, open-label, single-arm, phase II DESTINY-Breast01 trial (median follow-up 11.1 months) demonstrated durable antitumor activity with trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1). We report updated cumulative survival outcomes with a median follow-up of 26.5 months (data cut-off 26 March 2021).
科研通智能强力驱动
Strongly Powered by AbleSci AI